|
Asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The axis of miR-29c/B7-H3 plays an important role in children with asthma through regulating Th2/Th17 cell differentiation and may provide new targets for treatment of asthma.
|
30075787 |
2018 |
|
Asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In sharp contrast, B7-H3 KO mice developed severe ovalbumin (OVA)-induced asthma with characteristic infiltrations of eosinophils in the lung, increased IL-5 and IL-13 in lavage fluid, and elevated IgE anti-OVA antibodies in the blood.
|
26065426 |
2015 |
|
Autoimmune Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
CD276 (B7-H3) is a costimulatory molecule that plays a potent role in T cell responses, however, the role of B7-H3 in autoimmune diseases has not been elucidated.
|
25931383 |
2015 |
|
Autoimmune Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Our studies reveal that B7-H3 could affect different T cell subsets which have important implications for regulating pathogenesis and disease progression in human autoimmune disease.
|
26065426 |
2015 |
|
Autoimmune Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Our findings implicate a potential role of B7-H3 on dendritic cells in the induction of SLE and as a potential target for the treatment of autoimmune diseases.
|
31113935 |
2019 |
|
Autoimmune Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity.
|
28685773 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
B7-H3 in tissue samples was significantly higher in the prostate cancer group than in the benign prostatic hyperplasia group (mean±SEM 174.73±56.80 vs 82.69±46.19 ng/gm, p<0.001).
|
21784485 |
2011 |
|
Bladder Neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
To explore whether B7-H3 is an effective target for patients with bladder cancer, anti-CD3× anti-B7-H3 bispecific antibodies (B7-H3Bi-Ab) was armed with activated T cells (ATC) to kill bladder cancer cells.
|
30253078 |
2018 |
|
Bladder Neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Although previous studies have found abnormal expression of B7-H3 in human bladder cancer tissues, the exact role and molecular mechanism of B7-H3 in bladder cancer remain unknown.
|
28382144 |
2017 |
|
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
|
30655315 |
2019 |
|
Brain Stem Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the non-diffuse brainstem glioma group, none of the eight WHO grade I specimens showed B7-H3 immunoreactivity and nine of the 24 WHO grade II specimens (37.5 %) showed B7-H3 immunoreactivity.
|
23232807 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNAs targeting B7-H3 were identified by transfecting two breast cancer cell lines with a library of 810 miRNA mimics and quantifying changes of B7-H3 protein levels using protein lysate microarrays.
|
24577056 |
2014 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Blood from 50 patients suffering from breast cancer was analyzed for CETCs and the expression of B7-H3 and Ki-67 using the maintrac® method.
|
30226585 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, a method with high resolution and specificity for intraoperative margin assessment is needed.<b>Experimental Design:</b> First, quantitative immunofluorescence staining of B7-H3 expression was assessed in four pathologic stages of breast cancer progression of the MMTV-PyMT transgenic murine model.
|
29712688 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> B7-H3 is a promising target for both vascular and epithelial sPA imaging of breast cancer.
|
28529630 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.
|
26771843 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that silencing of B7-H3, via stable short hairpin RNA or transient short interfering RNA transfection, increased the sensitivity of multiple human breast cancer cell lines to paclitaxel as a result of enhanced drug-induced apoptosis.
|
21518725 |
2011 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study reports novel functions of B7-H3 in regulating breast cancer stem cell enrichment.
|
30082909 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In particular, B7-H3 (CD276), a cellular receptor expressed in breast cancer, was imaged via sPA and fluorescence molecular imaging to differentiate invasive tumors from normal glands in mice.
|
31082216 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative PCR results showed that the expression levels of CD24 and B7-H3 mRNA in breast cancer tissues were significantly higher than those in adjacent tissues (P<0.05).
|
29344150 |
2017 |
|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
However, the role of B7-H3 in oncogenesis and chemosensitivity of mantle cell lymphoma (MCL) remains unknown.
|
25872657 |
2015 |
|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The role of the type 1 transmembrane glycoprotein B7-H3 is controversial in tumorigenesis; thus, a better clarification of its involvement in cancer is crucial.
|
29924389 |
2018 |
|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In this review, we discuss current understanding of the diverse functions of B7-H3 in carcinogenesis and cancer progression, and consider future directions for designing cancer immunotherapeutic agents targeting B7-H3.
|
24013874 |
2014 |